C57BL/6J-Tlr9^M7Btlr/Mmjax

Stock number: 014534
Product name: CpG11
Research areas: Immunology, Inflammation and Autoimmunity Research

Description

In these ENU-induced Tlr9 mutant mice, macrophages do not produce tumor necrosis factor (TNF) alpha in response to stimulation with oligodeoxynucleotides containing CpG motifs. This mutant mouse strain may be useful in studies of the role of toll like receptor 9 (TLR9) in the immune system.

Detailed description

Homozygotes: Mice that are homozygous for this mutation are viable, fertile, normal in size and do not display any gross physical or behavioral abnormalities. In response to stimulation with oligodeoxynucleotides containing CpG motifs, macrophages do not produce tumor necrosis factor (TNF) alpha. This mutant mouse strain may be useful in studies of the role of toll like receptor 9 (TLR9) in the immune system.

For additional information, see The Scripps Research Institute Mutagenix website.

Heterozygote: Macrophages from heterozygous mice produce a reduced level of TNF-alpha in response to CpG stimulation.

Development

This missense point mutation was generated by ethylnitrosourea (ENU) mutagenesis in C57BL/6J males. Mutagenized males were outcrossed to C57BL/6J females. The mutation results in a T to C transition at position 1181 of the Tlr9 transcript. The mutation alters the corresponding amino acid from serine to proline at amino position 359 (S359P) in the eleventh leucine rich repeat. Upon arrival, mice were bred to C57BL/6J for at least 1 generation to establish the colony.

Allele

Symbol: Tlr9^M7Btlr
Name: mutation 7, Bruce Beutler
MGI accession ID: MGI:4838258
Generation method: Chemically induced (ENU)
Marker symbol: Tlr9
Marker name: toll-like receptor 9
Chromosome: 9
Strain of origin: C57BL/6J
Molecular note: This mutation, discovered in a screen of progeny of ethylnitrosourea (ENU) mutagenized mice for impaired responses to Toll-like receptor (TLR) ligands, has been identified as a T to C transition at nucleotide position 1181 of the transcript that is predicted to result in the replacement of serine by proline at amino acid position 359 of the protein (S359P), in the second leucine rich repeat.